The forefront of next generation synthetic bone graft products

The Company

Established in 2017, Biostone utilises proprietary technologies to produce next generation synthetic bone graft products that work in harmony with natural bone remodelling processes.

The Product

Our new product, si-Mochi, is osteoconductive, osteosimulative and is designed to enhance osteocytes formation – ready to use in a wide range of surgical applications. Watch our video below to learn more.

Our Journey

Biostone has attained FDA clearance for si-Mochi, and achieved both ISO13485 and MDSAP certification. We aim to increase our product portfolio and enter more territories in the near future.

Interested in learning more? Get in touch

On LinkedIn? Connect with us there

Biostone to Make Inaugural Appearance at OMTEC 2024 Exhibition

Success at NASS 2023

Biostone Achieves MDSAP Certification

Biostone at AAOS 2023 – Booth 5945!

Successful Meeting at NASS 2022

Come and visit Biostone at NASS 37th Annual Meeting 2022 in Chicago, IL USA